Human Pathology
Volume 41, Issue 6 , Pages 794-804 , June 2010

Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma

  • Mari Bunkholt Elstrand, MD

      Affiliations

    • Division of Obstetrics and Gynecology, Section for Gynecologic Oncology, Norwegian Radium Hospital, Oslo University Hospital, N-0310 Oslo, Norway
    • ,
  • Hiep Phuc Dong, MSc

      Affiliations

    • Division of Pathology, Norwegian Radium Hospital, Oslo University Hospital, N-0310 Oslo, Norway
    • ,
  • Elin Ødegaard, MD, PhD

      Affiliations

    • Division of Obstetrics and Gynecology, Section for Gynecologic Oncology, Norwegian Radium Hospital, Oslo University Hospital, N-0310 Oslo, Norway
    • ,
  • Arild Holth, BSc

      Affiliations

    • Division of Pathology, Norwegian Radium Hospital, Oslo University Hospital, N-0310 Oslo, Norway
    • ,
  • Sivan Elloul, MSc

      Affiliations

    • Department of Pharmacology and Experimental Therapeutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 91120, Israel
    • ,
  • Reuven Reich, PhD

      Affiliations

    • Department of Pharmacology and Experimental Therapeutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 91120, Israel
    • ,
  • Claes G. Tropé, MD, PhD

      Affiliations

    • Division of Obstetrics and Gynecology, Section for Gynecologic Oncology, Norwegian Radium Hospital, Oslo University Hospital, N-0310 Oslo, Norway
    • Faculty Division Radiumhospitalet, the Medical Faculty, University of Oslo, N-0316 Oslo, Norway
    • ,
  • Ben Davidson, MD, PhD

      Affiliations

    • Division of Pathology, Norwegian Radium Hospital, Oslo University Hospital, N-0310 Oslo, Norway
    • Faculty Division Radiumhospitalet, the Medical Faculty, University of Oslo, N-0316 Oslo, Norway
    • Corresponding Author InformationCorresponding author. Department of Pathology, Norwegian Radium Hospital, Rikshospitalet University Hospital, Montebello, N-0310 Oslo, Norway.

Received 29 May 2009 ,Revised 28 August 2009 ,Accepted 22 September 2009.

References 

  1. Ozols RF. Treatment goals in ovarian cancer. Int J Gynecol Cancer. 2005;15(Suppl 1):3–11
  2. Cancer in Norway . In: Cancer incidence mortality survival and prevalence. Norway Oslo: Cancer Registry of Norway; 2006;p. 2007
  3. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003;3:502–516
  4. Viktorsson K, Lewensohn R, Zhivotovsky B. Apoptotic pathways and therapy resistance in human malignancies. Adv Cancer Res. 2005;94:143–196
  5. Davidson B. Biological characteristics of cancers involving the serosal cavities. Crit Rev Oncog. 2007;13:189–227
  6. Makar AP, Baekelandt M, Tropé CG, Kristensen GB. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol. 1995;56:175–180
  7. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature. 2001;271:409–413
  8. Vivanco I, Sawyers C. The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nat Rev Cancer. 2002;2:489–501
  9. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer. 2006;6:184–192
  10. Chow LM, Baker SJ. PTEN function in normal and neoplastic growth. Cancer Lett. 2006;241:184–196
  11. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res. 2005;94:29–86
  12. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med. 2005;9:59–71
  13. Thompson JE, Thompson CB. Putting the rap on Akt. J Clin Oncol. 2004;22:4217–4226
  14. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12:9–22
  15. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol. 2008;8:393–412
  16. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307:1098–1101
  17. Arboleda MJ, Lyons JF, Kabbinavar FF, et al. Overexpression of AKT2/protein kinase Bβ leads to up-regulation of β1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res. 2003;63:196–206
  18. Page C, Lin HJ, Jin Y, et al. Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res. 2000;20:407–416
  19. Altomare DA, Wang HQ, Skele KL, et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene. 2004;23:5853–5857
  20. Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res. 2002;62:1087–1092
  21. Mabuchi S, Altomare DA, Cheung M, et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res. 2007;13:4261–4270
  22. Huynh H, Teo CC, Soo KC. Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer. Mol Cancer Ther. 2007;6:2959–2966
  23. Bellacosa A, de Feo D, Godwin AK, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer. 1995;64:280–285
  24. Thompson FH, Nelson MA, Trent JM, et al. Amplification of 19q13.1-q13.2 sequences in ovarian cancer. G-band, FISH, and molecular studies. Cancer Genet Cytogenet. 1996;87:55–62
  25. Kurose K, Zhou XP, Araki T, Cannistra SA, Maher ER, Eng C. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol. 2001;158:2097–2106
  26. Noske A, Lindenberg JL, Darb-Esfahani S, et al. Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis. Oncol Rep. 2008;20:1409–1417
  27. Sun M, Wang G, Paciga JE, et al. AKT1/PKB kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol. 2001;159:431–437
  28. Castellvi J, Garcia A, Rojo F, et al. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer. 2006;107:1801–1811
  29. Oda Y, Ohishi Y, Basaki Y, et al. Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: their correlation with activated Akt, LRP/MVP and P-glycoprotein expression. Cancer Sci. 2007;98:1020–1026
  30. Guo RX, Qiao YH, Zhou Y, Li LX, Shi HR, Chen KS. Increased staining for phosphorylated AKT and nuclear factor–kappaB p65 and their relationship with prognosis in epithelial ovarian cancer. Pathol Int. 2008;58:749–756
  31. Woenckhaus J, Steger K, Sturm K, Münstedt K, Franke FE, Fenic I. Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer. Virchows Arch. 2007;450:387–395
  32. Wang Y, Kristensen GB, Helland A, Nesland JM, Børresen-Dale AL, Holm R. Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas. Am J Clin Pathol. 2005;124:392–401
  33. Davidson B, Nielsen S, Christensen J, et al. The role of Desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol. 2001;25:1405–1412
  34. Dong HP, Kleinberg L, Davidson B, Risberg B. Methods for simultaneous measurement of apoptosis and cell surface phenotype of epithelial cells in effusions by flow cytometry. Nat Protoc. 2008;3:955–964
  35. Dong HP, Holth A, Berner A, Davidson B, Risberg B. Flow cytometric immunophenotyping of epithelial cancer cells in effusions- technical considerations and pitfalls. Cytometry B Clin Cytom. 2007;72B:332–343
  36. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumor EORTC; National Cancer Institute of United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–216
  37. Vergote I, Rustin GJ, Eisenhauer EA, et al. Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer): Gynecologic Cancer Intergroup. J Natl Cancer Inst. 2000;92:1534–1535
  38. Kim RH, Peters M, Jang Y, et al. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell. 2005;7:263–273
  39. Davidson B, Hadar R, Schlossberg A, et al. Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma. Hum Pathol. 2008;39:87–95
  40. Vasseur S, Afzal S, Tardivel-Lacombe J, et al. DJ-1/PARK7 is an important mediator of hypoxia-induced cellular responses. Proc Natl Acad Sci U S A. 2009;106:1111–1116
  41. Kleinberg L, Flørenes VA, Silins I, et al. Nuclear expression of Survivin is associated with improved survival in metastatic ovarian carcinoma. Cancer. 2007;109:228–238
  42. Davidson B, Espina V, Flørenes VA, et al. Proteomic profiling of malignant ovarian cancer effusions: survival and injury pathways discriminate clinical outcome. Clin Cancer Res. 2006;12:791–799
  43. Elloul S, Elstrand MB, Nesland JM, et al. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer. 2005;103:1631–1643

☆ Financial acknowledgement: This work was supported by grants from the Norwegian Cancer Society (Olso, Norway), the Health Region of South-Eastern Norway (Hamar, Norway), and the Inger and Jon Fredriksen Foundation for Ovarian Cancer Research (Olso, Norway).

PII: S0046-8177(09)00426-2

doi: 10.1016/j.humpath.2009.09.017

Human Pathology
Volume 41, Issue 6 , Pages 794-804 , June 2010

Article Tools

* Image Usage & Resolution